Page 335 - Drug Class Review

Final Report Update 1 Drug Effectiveness Review Project

APPENDIX E. Abstract-only Studies (not included)

1. Bayer AJ, Rossor M, Hecker J, Gauthier S, Burns A, Petite H, et al. Donepezil improves functional
activity in patients with Alzheimer's Disease. XXIst Collegium Internationale Neuro-
psychopharmacologicum, Glasgow, Scotland. 12th-16th July, 1998. 1998(ABSTRACT REF:
PW11015).

2. Cummings J, Anand R, Koumaras B, Hartman R. Rivastigmine provides behavioral benefits to
Alzheimer's disease patients residing in a nursing home: findings from a 26-week trial. Neurology
2000;54(Suppl 3):A468-69.

3. Doody R, Clark C, Farlow M, et al. Chronic Donepezil Treatment is Associated with Slowed
Cognitive Decline in Alzheimer's disease patients. Neurobiology of Aging 1998;19(Suppl 4):S303.

4. Doraiswamy PM, Anand R, and HR. Cognitive effects of rivastigmine in patients with mild to
moderate alzheimer's disease compared to those with moderately-severe to severe AD. Clinical
Neuropsychological Assessment 2000;1(6):12.

5. Doraiswamy PM, Anand R, and HR. Long term cognitive effects in alzheimer's disease patients
stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropsychological
Assessment 2000;1(6):14.

6. Engedal K, Soininen H, Verhey F, Waldemar G, Winblad B, Wimo A, et al. Donepezil improved or
stabilized cognition over one year in patients with mild and moderate alzheimer's disease. Journal of
the European College of Neuropsychopharmacology (Abstracts of the 13th ECNP Congress,
Munich, September 9-13, 2000) 2000;10(Supplement 3):S368.

7. Farlow M, Tariot P, Grossberg G, Gergel I, Graham S, Jin J. Memantine/donepezil dual therapy is
superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's disease.
Neurology 2003;60(Suppl 1):A412.

8. Froelich L, Gertz HJ, Heun R, Heuser I, Jendroska K, Kornhuber J, et al. Donepezil for alzheimer's
disease - the donald study - a multicenter 24 weeks clinical trial in germany. Journal of the European
College of Neuropsychopharmacology (Abstracts of the 13th ECNP Congress, Munich, September
9-13, 2000) 2000;10(Supplement 3):S360.

9. Grimley EJ, Wilcock GK, Whitehead A, Birks J, Perdomo C, Pratt R. Donepezil: a meta-analysis of
individual patient data from randomised controlled trials in the treatment of patients with mild to
moderate alzheimer's disease. JNS 2001;187(Suppl. 1).

10. Mastey V, Wimo A, Winblad B, Haglund A, Jacobson L, Miceli R, et al. Donepezil reduces the time
caregivers spend providing care: results of a one-year, double-blind, randomized trial in patients with
mild to moderate Alzheimer's disease. 14th Annual Meeting of the American Association for
Geriatric Psychiatry; 2001 23rd-26th February; San Francisco, CA, USA 2001.

11. McRae T, Knopman D, Duttagupta S, Ieni J, Provenzano G. Donepezil delays time to nursing home
placement in patients with Alzheimer's disease. 14th Annual Meeting of the American Association
for Geriatric Psychiatry; 2001 23rd-26th February; San Francisco, CA, USA 2001.

12. McRae T, Knopman D, Mastey V, Ieni J, Provenzano G. Donepezil is strongly associated with
delayed nursing home placement in patients with alzheimer's disease. JNS 2001;187(Suppl. 1).

Alzheimer's Drugs Page 202 of 205